Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face

ClinicalTrials.gov ID: NCT04085367

Public ClinicalTrials.gov record NCT04085367. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream in the Treatment of Thin and Moderately Thick, Non-hyperkeratotic, Non-pigmented Actinic Keratosis (AK) of the Face and Scalp When Using Daylight Photodynamic Therapy (DL-PDT)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl aminolevulinate hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratosis of the face and scalp when using daylight photodynamic therapy (DL-PDT).

Study identification

NCT ID
NCT04085367
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Galderma R&D
Industry
Enrollment
557 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 29, 2019
Primary completion
Mar 2, 2021
Completion
Apr 6, 2021
Last update posted
Mar 31, 2022

2019 – 2021

United States locations

U.S. sites
59
U.S. states
28
U.S. cities
55
Facility City State ZIP Site status
Galderma Investigational Site (Site 8768) Tucson Arizona 85718
Galderma Investigational Site (Site 8447) Fort Smith Arkansas 72916-6103
Galderma Investigational Site (Site 8577) Encinitas California 92024
Galderma Investigational Site (Site 8636) Fountain Valley California 92708
Galderma Investigational Site (Site 8224) Fremont California 94538
Galderma Investigational Site (Site 8114) Fresno California 93720
Galderma Investigational Site (Site 8758) San Diego California 92121
Galderma Investigational Site (Site 8608) Santa Monica California 90404
Galderma Investigational Site (Site 8778) Denver Colorado 80210
Galderma Investigational Site (Site 8440) Greenwood Village Colorado 80111
Galderma Investigational Site (Site 8479) Bradenton Florida 34209
Galderma Investigational Site (Site 8770) Lehigh Acres Florida 33936
Galderma Investigational Site (Site 8656) Miami Florida 33137
Galderma Investigational Site (Site 8765) North Miami Beach Florida 33162
Galderma Investigation Site (Site 8769) Palm Springs Florida 33461
Galderma Investigational Site (Site 8734) Pembroke Pines Florida 33028
Galderma Investigational Site (Site 8529) Sanford Florida 32771
Galderma Investigational Site (Site 8126) West Palm Beach Florida 33401
Galderma Investigational Site (Site 8683) Atlanta Georgia 30342-1418
Galderma Investigational Site (Site 8860) Atlanta Georgia 30342
Galderma Investigational Site (Site 8667) Columbus Georgia 31904
Galderma Investigational Site (Site 8755) Boise Idaho 83704
Galderma Investigational Site (Site 8838) Darien Illinois 60561
Galderma Investigational Site (Site 8724) Louisville Kentucky 40241
Galderma Investigational Site (Site 8208) Beverly Massachusetts 01915
Galderma Investigational Site (Site 8574) Clarkston Michigan 48346-3198
Galderma Investigation Site (Site 8757) Saint Joseph Michigan 49085
Galderma Investigational Site (Site 8762) Edina Minnesota 55424-1200
Galderma Investigational Site (Site 8140) New Brighton Minnesota 55112
Galderma Investigational Site (Site 8219) St Louis Missouri 63141
Galderma Investigational Site (Site 8869) St Louis Missouri 63141
Galderma Investigational Site (Site 8048) Omaha Nebraska 68144
Galderma Investigational Site (Site 8420) Portsmouth New Hampshire 03801
Galderma Investigational Site (Site 8759) Albuquerque New Mexico 87102
Galderma Investigational Site (Site 8242) Brooklyn New York 11203
Galderma Investigational Site (Site 8733) New York New York 10022
Galderma Investigational Site (Site 8279) New York New York 10075
Galderma Investigational Site (Site 8566) Charlotte North Carolina 28277
Galderma Investigational Site (Site 8726) Wilmington North Carolina 28405-3176
Galderma Investigational Site (Site 8595) Dublin Ohio 43016
Galderma Investiational Site (Site 8212) Portland Oregon 97210-2996
Galderma Investigational Site (Site 8255) Philadelphia Pennsylvania 19103
Galderma Investigational Site (Site 8721) Pittsburgh Pennsylvania 15213
Galderma Investigational Site (Site 8754) Sugarloaf Pennsylvania 18249
Galderma Investigational Site (Site 8777) Charleston South Carolina 29407
Galderma Investigational Site (Site 8207) Nashville Tennessee 37215
Galderma Investigational Site (Site 8076) Austin Texas 78759
Galderma Investigational Site (Site 8139) College Station Texas 77845
Galderma Investigational Site (Site 8664) Frisco Texas 75034
Galderma Investigational Site (Site # 8576) Houston Texas 77056
Galderma Investigational Site (Site 8546) Pflugerville Texas 78660-3519
Galderma Investigational Site (Site 8672) Salt Lake City Utah 84117
Galderma Investigational Site (Site 8776) St. George Utah 84790
Galderma Investigational Site (Site 8761) West Jordan Utah 84101
Galderma Investigational Site (Site 8057) Lynchburg Virginia 24501
Galderma Investigational Site (Site 8779) Burien Washington 98168
Galderma Investigational Site (Site 8039) Spokane Washington 99202
Galderma Investigational Site (Site 8760) Spokane Washington 99202
Galderma Investigational Site (Site 8725) Morgantown West Virginia 26505

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04085367, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 31, 2022 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04085367 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →